目的评价原型株SARS-CoV-2灭活疫苗免疫BALB/c小鼠后对Delta株病毒的体液及细胞免疫效果,为现有疫苗对变异株的保护效果评价以及研发更加安全有效的疫苗提供参考。方法将SARS-CoV-2灭活疫苗经腹腔免疫雌性BALB/c小鼠2次,间隔14 d,以免疫...目的评价原型株SARS-CoV-2灭活疫苗免疫BALB/c小鼠后对Delta株病毒的体液及细胞免疫效果,为现有疫苗对变异株的保护效果评价以及研发更加安全有效的疫苗提供参考。方法将SARS-CoV-2灭活疫苗经腹腔免疫雌性BALB/c小鼠2次,间隔14 d,以免疫PBS作为对照,每组10只。初次免疫后第7、14、21、28、35和42天采集血清,间接ELISA法检测血清中针对Delta株病毒S和N蛋白的结合抗体效价,微量中和试验检测针对Delta株病毒的中和抗体效价。初次免疫后第42天,取小鼠脾脏,进行Elispot检测,评价细胞免疫水平。结果初次免疫后第7天即可检测到S蛋白结合抗体,加强免疫后抗体效价进一步升高,至第21天抗体几何平均滴度(geometric mean titer,GMT)为89144;而初次免疫后N蛋白结合抗体水平较低,加强免疫后迅速升高,与S蛋白抗体水平相当。初次免疫后第7、14天小鼠中和抗体阳转数为4/10和8/10,加强免疫后全部小鼠抗体阳转,中和抗体GMT达391。初次免疫后第42天,疫苗组IFNγ和IL-2平均斑点数均显著高于对照组(t分别为8.094和13.08,P均<0.0001)。结论SARS-CoV-2灭活疫苗2次免疫能够有效刺激小鼠产生针对Delta株病毒的体液免疫和细胞免疫。展开更多
The novel coronavirus (SARS-Cov-2) delayed the Tokyo 2020 Games. The traveling by air, rail, road, and sea inside and outside the countries has stopped to contain the virus. The amount of money lost and assistance nee...The novel coronavirus (SARS-Cov-2) delayed the Tokyo 2020 Games. The traveling by air, rail, road, and sea inside and outside the countries has stopped to contain the virus. The amount of money lost and assistance needed to reschedule and conduct the Games in 2021 have been estimated. With more than one billion population is under the semi-locked down and movement of people is restricted, athletes cannot prepare at home and participate in the Games. The COVID-19 outbreak has spread around the world;it has already infected 5.7 million people and caused 355,000 deaths reported on May 28, 2020 and the figures increasing every day. The publication of this article is important as the postponement of the Olympics has costed Japan $6 billion and the organizers have worked very hard for seven years. If the Games are conducted in 2021, it will be the—beginning of the world recovery—from big COVID-19 pandemic. In this communication, the development in testing, treatment, and vaccine preparation for SARS-Cov-2 have occurred so far in different countries and companies have been discussed to know the possibilities if the pandemic can be overcome and the Games can be conducted in 2021.展开更多
目的分析自噬与新型冠状病毒感染(COVID-19)研究中的主要研究主题和热点,揭示该领域的研究趋势和未来方向。方法采用Web of Science核心数据库,检索自2020年1月1日至2024年4月18日发表的与自噬和COVID-19相关的英文文献。利用文献计量...目的分析自噬与新型冠状病毒感染(COVID-19)研究中的主要研究主题和热点,揭示该领域的研究趋势和未来方向。方法采用Web of Science核心数据库,检索自2020年1月1日至2024年4月18日发表的与自噬和COVID-19相关的英文文献。利用文献计量学方法和CiteSpace软件工具进行文献可视化分析。结果自2020年以来,自噬与COVID-19相关的文献数量呈爆发性增长,总共纳入514篇文献。发表论文最多的机构为中国科学院,研究影响最大的科研机构为加州大学系统。研究热点包括自噬在SARS-CoV-2感染中的作用、自噬相关的信号通路、自噬与炎症反应的关系以及自噬作为潜在治疗靶点的研究。通过关键词分析生成的知识图谱显示了自噬、SARS-CoV-2、炎症、抗病毒反应等关键词之间的关联。关键词的聚类分析揭示了自噬在病毒复制、抗炎和免疫调节以及细胞死亡中的作用是当前研究的主要方向。结论自噬在COVID-19的发病机制和治疗中扮演着重要角色。可视化分析为理解自噬与COVID-19复杂的相互作用提供了新的视角,并指出自噬在长新冠和新冠后综合征中的作用是未来研究的主要方向。展开更多
Dear Editor,Historically,dipeptidyl peptidase 4(DPP4),found in alveolar regions,has been recognized as the primary receptor for several merbecoviruses like MERS-CoV(Meyerholz et al.,2016).However,angiotensin-convertin...Dear Editor,Historically,dipeptidyl peptidase 4(DPP4),found in alveolar regions,has been recognized as the primary receptor for several merbecoviruses like MERS-CoV(Meyerholz et al.,2016).However,angiotensin-converting enzyme 2(ACE2),highly expressed in the motile cilia of human airway epithelial cells(Sungnak et al.,2020),has been identified as the functional receptor for sarbecoviruses(e.g.,SARS-CoV-2,SARS-CoV)and setracoviruses(e.g.,HCoV-NL63).Recent studies have shown that some bat-circulating MERS-related coronaviruses(MERSr-CoVs),such as MOW15-22,PnNL2018B and HKU5,can use ACE2 to enter cells(Ma et al.,2025;Park et al.,2025).Even more worrying is that one novel bat-infecting merbecovirus HKU5-CoV lineage 2(BtHKU5-CoV-2)has been reported to use human ACE2 as a cell entry receptor(Chen et al.,2025).These ACE2-utilizing merbecoviruses expand the diversity,geographic distribution,and transmission potential of coronaviruses,posing a significant threat of spillover to humans.If an ACE2-utilizing MERSr-CoV acquire the high lethality of MERS-CoV and the high transmissibility of SARS-CoV-2 using ACE2 as a receptor,it could trigger a global pandemic with catastrophic consequences for humanity.Therefore,it is essential to evaluate serological cross-reactivity in sera from SARS-CoV-2-infected individuals against ACE2-using MERSr-CoVs,and urgent to develop preventive vaccines and pan-coronavirus antivirals confront the potential threat(Jiang and Wu,2025).展开更多
The emergence of the SARS-CoV-2 virus resulted in a health and economic crisis worldwide. Although everyone is susceptible to COVID-19, the elderly have compromised immune systems and often suffer from chronic underly...The emergence of the SARS-CoV-2 virus resulted in a health and economic crisis worldwide. Although everyone is susceptible to COVID-19, the elderly have compromised immune systems and often suffer from chronic underlying diseases, which makes them more vulnerable. This study aims to assess variation in COVID-19 vaccine distribution patterns across different age groups in European countries and to understand the extent to which European countries have prioritized vulnerable age groups (age > 70) in their vaccination programs. The study utilized open data from the European Center for Disease Prevention and Control (ECDC) and employed an observational, retrospective study design to examine the distribution of the COVID-19 vaccine among various age groups in several European countries from September 2021 to September 2023. Results reveal that vaccination rates increase with age, peaking at the 25 - 49 age group (1.34 × 10−4), after which there was a decline in vaccination rate. Analysis of variance (ANOVA) was used to investigate the equality of vaccination rates across the 29 countries in Europe, which resulted in a p-value of 70) during the study period as no country achieved the 70% coverage aimed by WHO. Continuous efforts must be made to ensure larger coverage of COVID-19 vaccination among this vulnerable population in order to protect them from severe outcomes in this region.展开更多
The new Coronavirus disease or COVID-19 is a contagious viral/immune-logical systemic disorder with predominantly respiratory features caused by human infection with SARS-CoV-2, which is rapidly spreading from person-...The new Coronavirus disease or COVID-19 is a contagious viral/immune-logical systemic disorder with predominantly respiratory features caused by human infection with SARS-CoV-2, which is rapidly spreading from person-to-person all around the world as a pandemic. The new outbreak of COVID-19 first appeared in Wuhan, China in December 2019. This virus is transmitted from human to human in various ways including air, aerosol, touching, and fecal-oral ways. The SARS-CoV-2 survives for several days in the environment. The SARS-CoV-2 virus multiplies within the cells of mouth-throat or nose-throat, and despite the production of antibodies by the human immune system, if the virus continues to multiply and progress, it will enter the bloodstream and reach its target organ, the lungs. It takes an incubation period of one to fourteen days for the initial symptoms/signs of disease to appear as fever, dry cough, and fatigue. Finally, shortness of breath due to pneumonia/pneumonitis with or without Acute Respiratory Distress Syndrome (ARDS) causes the patient to be hospitalized and transferred to ICU. Older people with underlying disorders account for the majority of deaths from COVID-19, while children under the age of 15 - 20 are the main carriers of the SARS-CoV-2. About 40% of patients with COVID-19 are asymptomatic and, 40% mild, 15%;severe, and 5% are critical COVID-19. COVID-19 Molecular Diagnostic Tests and COVID-19 Antibody Tests are two types of diagnostic kit tests for identification of the SARS-CoV-2 and the High Resolution Computerised Tomography (HRCT) scanning of lungs is the best imaging method for detecting pneumonia/pneumonitis and assessing its severity. This paper is intended to present a health system called COVID-19 Referral System for screening and developing very sensitive diagnostic criteria as Persian Gulf Criteria for diagnosis of COVID-19. By using these two methods and performing the SARS-CoV-2 kit tests more and more widely, and performing accurate isolation of patients and virus carriers and complete quarantine of red zones, it is possible to successfully control the SARS-CoV-2 epidemics.展开更多
文摘目的评价原型株SARS-CoV-2灭活疫苗免疫BALB/c小鼠后对Delta株病毒的体液及细胞免疫效果,为现有疫苗对变异株的保护效果评价以及研发更加安全有效的疫苗提供参考。方法将SARS-CoV-2灭活疫苗经腹腔免疫雌性BALB/c小鼠2次,间隔14 d,以免疫PBS作为对照,每组10只。初次免疫后第7、14、21、28、35和42天采集血清,间接ELISA法检测血清中针对Delta株病毒S和N蛋白的结合抗体效价,微量中和试验检测针对Delta株病毒的中和抗体效价。初次免疫后第42天,取小鼠脾脏,进行Elispot检测,评价细胞免疫水平。结果初次免疫后第7天即可检测到S蛋白结合抗体,加强免疫后抗体效价进一步升高,至第21天抗体几何平均滴度(geometric mean titer,GMT)为89144;而初次免疫后N蛋白结合抗体水平较低,加强免疫后迅速升高,与S蛋白抗体水平相当。初次免疫后第7、14天小鼠中和抗体阳转数为4/10和8/10,加强免疫后全部小鼠抗体阳转,中和抗体GMT达391。初次免疫后第42天,疫苗组IFNγ和IL-2平均斑点数均显著高于对照组(t分别为8.094和13.08,P均<0.0001)。结论SARS-CoV-2灭活疫苗2次免疫能够有效刺激小鼠产生针对Delta株病毒的体液免疫和细胞免疫。
文摘The novel coronavirus (SARS-Cov-2) delayed the Tokyo 2020 Games. The traveling by air, rail, road, and sea inside and outside the countries has stopped to contain the virus. The amount of money lost and assistance needed to reschedule and conduct the Games in 2021 have been estimated. With more than one billion population is under the semi-locked down and movement of people is restricted, athletes cannot prepare at home and participate in the Games. The COVID-19 outbreak has spread around the world;it has already infected 5.7 million people and caused 355,000 deaths reported on May 28, 2020 and the figures increasing every day. The publication of this article is important as the postponement of the Olympics has costed Japan $6 billion and the organizers have worked very hard for seven years. If the Games are conducted in 2021, it will be the—beginning of the world recovery—from big COVID-19 pandemic. In this communication, the development in testing, treatment, and vaccine preparation for SARS-Cov-2 have occurred so far in different countries and companies have been discussed to know the possibilities if the pandemic can be overcome and the Games can be conducted in 2021.
文摘目的分析自噬与新型冠状病毒感染(COVID-19)研究中的主要研究主题和热点,揭示该领域的研究趋势和未来方向。方法采用Web of Science核心数据库,检索自2020年1月1日至2024年4月18日发表的与自噬和COVID-19相关的英文文献。利用文献计量学方法和CiteSpace软件工具进行文献可视化分析。结果自2020年以来,自噬与COVID-19相关的文献数量呈爆发性增长,总共纳入514篇文献。发表论文最多的机构为中国科学院,研究影响最大的科研机构为加州大学系统。研究热点包括自噬在SARS-CoV-2感染中的作用、自噬相关的信号通路、自噬与炎症反应的关系以及自噬作为潜在治疗靶点的研究。通过关键词分析生成的知识图谱显示了自噬、SARS-CoV-2、炎症、抗病毒反应等关键词之间的关联。关键词的聚类分析揭示了自噬在病毒复制、抗炎和免疫调节以及细胞死亡中的作用是当前研究的主要方向。结论自噬在COVID-19的发病机制和治疗中扮演着重要角色。可视化分析为理解自噬与COVID-19复杂的相互作用提供了新的视角,并指出自噬在长新冠和新冠后综合征中的作用是未来研究的主要方向。
文摘Dear Editor,Historically,dipeptidyl peptidase 4(DPP4),found in alveolar regions,has been recognized as the primary receptor for several merbecoviruses like MERS-CoV(Meyerholz et al.,2016).However,angiotensin-converting enzyme 2(ACE2),highly expressed in the motile cilia of human airway epithelial cells(Sungnak et al.,2020),has been identified as the functional receptor for sarbecoviruses(e.g.,SARS-CoV-2,SARS-CoV)and setracoviruses(e.g.,HCoV-NL63).Recent studies have shown that some bat-circulating MERS-related coronaviruses(MERSr-CoVs),such as MOW15-22,PnNL2018B and HKU5,can use ACE2 to enter cells(Ma et al.,2025;Park et al.,2025).Even more worrying is that one novel bat-infecting merbecovirus HKU5-CoV lineage 2(BtHKU5-CoV-2)has been reported to use human ACE2 as a cell entry receptor(Chen et al.,2025).These ACE2-utilizing merbecoviruses expand the diversity,geographic distribution,and transmission potential of coronaviruses,posing a significant threat of spillover to humans.If an ACE2-utilizing MERSr-CoV acquire the high lethality of MERS-CoV and the high transmissibility of SARS-CoV-2 using ACE2 as a receptor,it could trigger a global pandemic with catastrophic consequences for humanity.Therefore,it is essential to evaluate serological cross-reactivity in sera from SARS-CoV-2-infected individuals against ACE2-using MERSr-CoVs,and urgent to develop preventive vaccines and pan-coronavirus antivirals confront the potential threat(Jiang and Wu,2025).
文摘The emergence of the SARS-CoV-2 virus resulted in a health and economic crisis worldwide. Although everyone is susceptible to COVID-19, the elderly have compromised immune systems and often suffer from chronic underlying diseases, which makes them more vulnerable. This study aims to assess variation in COVID-19 vaccine distribution patterns across different age groups in European countries and to understand the extent to which European countries have prioritized vulnerable age groups (age > 70) in their vaccination programs. The study utilized open data from the European Center for Disease Prevention and Control (ECDC) and employed an observational, retrospective study design to examine the distribution of the COVID-19 vaccine among various age groups in several European countries from September 2021 to September 2023. Results reveal that vaccination rates increase with age, peaking at the 25 - 49 age group (1.34 × 10−4), after which there was a decline in vaccination rate. Analysis of variance (ANOVA) was used to investigate the equality of vaccination rates across the 29 countries in Europe, which resulted in a p-value of 70) during the study period as no country achieved the 70% coverage aimed by WHO. Continuous efforts must be made to ensure larger coverage of COVID-19 vaccination among this vulnerable population in order to protect them from severe outcomes in this region.
文摘The new Coronavirus disease or COVID-19 is a contagious viral/immune-logical systemic disorder with predominantly respiratory features caused by human infection with SARS-CoV-2, which is rapidly spreading from person-to-person all around the world as a pandemic. The new outbreak of COVID-19 first appeared in Wuhan, China in December 2019. This virus is transmitted from human to human in various ways including air, aerosol, touching, and fecal-oral ways. The SARS-CoV-2 survives for several days in the environment. The SARS-CoV-2 virus multiplies within the cells of mouth-throat or nose-throat, and despite the production of antibodies by the human immune system, if the virus continues to multiply and progress, it will enter the bloodstream and reach its target organ, the lungs. It takes an incubation period of one to fourteen days for the initial symptoms/signs of disease to appear as fever, dry cough, and fatigue. Finally, shortness of breath due to pneumonia/pneumonitis with or without Acute Respiratory Distress Syndrome (ARDS) causes the patient to be hospitalized and transferred to ICU. Older people with underlying disorders account for the majority of deaths from COVID-19, while children under the age of 15 - 20 are the main carriers of the SARS-CoV-2. About 40% of patients with COVID-19 are asymptomatic and, 40% mild, 15%;severe, and 5% are critical COVID-19. COVID-19 Molecular Diagnostic Tests and COVID-19 Antibody Tests are two types of diagnostic kit tests for identification of the SARS-CoV-2 and the High Resolution Computerised Tomography (HRCT) scanning of lungs is the best imaging method for detecting pneumonia/pneumonitis and assessing its severity. This paper is intended to present a health system called COVID-19 Referral System for screening and developing very sensitive diagnostic criteria as Persian Gulf Criteria for diagnosis of COVID-19. By using these two methods and performing the SARS-CoV-2 kit tests more and more widely, and performing accurate isolation of patients and virus carriers and complete quarantine of red zones, it is possible to successfully control the SARS-CoV-2 epidemics.
